Felicity Thomas

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

Novo Nordisk’s obesity treatment has been so successful the company is now top of the ‘value pile’ in Europe.

In this episode of Drug Digest, Pharmaceutical Technology’s European/Senior Editor, Felicity Thomas, discusses small-molecule APIs, excipients, and formulation advances, including a discussion about novel approaches and solutions to pediatric formulations and taste-masking, a rundown of the fundamental stages of gaining a certificate of suitability for APIs, and a deliberation on the biggest trends impacting the industry and key sessions to visit while at CPHI, with several key industry experts.

Otsuka Pharmaceutical Europe and Astex Pharmaceuticals have announced the approval of INAQOVI by the European Commission.

Samsung Biologics and Bristol Myers Squibb have further expanded their strategic manufacturing agreement to include the large-scale manufacture of an antibody cancer drug substance.

Modular facilities allow for a certain amount of flexibility and reconfiguration options.

A structured cleaning procedure is essential to ensure the effective cleaning of equipment.

The pandemic and shifting focus to more complex therapeutics are driving growth in the outsourced formulation development services market.

European vaccine manufacturing is being boosted with high level investments.

The industry is taking steps to automate the final product inspection process for complex therapeutics.

Current good manufacturing practices for oral solid dosage forms protect the product from contamination and potential errors.

Only a significant joint effort across the supply chain will help to make healthcare more sustainable and reduce the impact of climate change on global health.

In this episode, David Tisi and Reenal Gandhi provide expert insights into advances and innovations changing the drug dosage form landscape.

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

Meletios Therapeutics has been awarded with funding worth €1.2 million (US$1.3 million) from Bpifrance’s Deeptech development program.

Syngene has acquired a multi-modal biologics drug substance manufacturing facility in Bangalore, India, from Stelis Biopharma.

To overcome the challenges of the widening range and scope of products that require aseptic processing and the evolving regulatory landscape in this field, companies should deepen their knowledge base on best practices.

The UK and EU have negotiated a new draft deal for Britain to re-join the Horizon Europe research programme.

Aenova has opened a new building for the production of highly potent APIs in Germany.

Manufacturers must figure out how flexible they need to be to meet the numerous new requirements of the changing therapeutic and regulatory landscapes.

The future is set to be a running theme for this year’s CPHI event, which will take place in-person at the Fira Barcelona Gran Via in Spain between 24–26 October 2023.

Despite being a relatively small nation, Switzerland is booming for biotech innovation.

Here is a small selection of some of the inspiring places to visit while in Barcelona, Spain.

A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.

Alvotech and Advanz Pharma have signed a strategic partnership agreement for the supply and commercialization of five biosimilar candidates in Europe.

UK government supports AMR research with significant cash injection, provided through the Global AMR Innovation Fund (GAMRIF).

ILC Therapeutics has entered into a strategic partnership with Dechra Pharmaceuticals to develop an atopic dermatitis treatment for dogs.

Felicity Thomas, European/Senior Editor, Pharm Tech Group, and Andy Dumelow, Head of Technical Sales, I Holland, chat about tablet tooling maintenance in this brief podcast.

The UK’s National Institute for Health and Care Excellence has recommended dapagliflozin (Forxiga) from AstraZeneca as a treatment option for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.

The UK and Switzerland are negotiating a modern free trade agreement.